A Multi-Center, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Olutasidenib on the Pharmacokinetics of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Substrates in Patients With IDH1 Mutation-Positive Malignancies Being Treated With Olutasidenib

This study is looking at how a cancer medication called olutasidenib interacts with other common substances in your body. By understanding how the liver processes these medicines together, doctors can ensure patients receive safer and more effective treatment for their cancer.

You may be eligible if you are 18 or older, have a cancer with a specific genetic marker called IDH1, and are generally healthy enough to manage daily activities. Participants must also be willing to follow specific rules regarding smoking, alcohol consumption, and family planning.

You will receive the study medication along with a group of safe test substances that act like a 'cocktail' to help researchers track how your liver works. The team will perform tests to monitor your health closely and see how your body processes these different medications.

The study is currently recruiting new participants and is being conducted at medical centers in Orange, California, and New York, New York.